Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | QPCT | Q16769 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657834 | 0.82 | MAPT (0.52) | CYP19A1KMT2ATP53KDM4ETSHR | |
| SCHEMBL9663626 | 0.78 | CYP19A1 (1.00) | CYP19A1KMT2AMAOAMAOBQPCT | |
| SCHEMBL5655088 | 0.78 | TP53 (0.72) | CYP19A1KMT2ATP53KDM4ETSHR | |
| SCHEMBL76423 | 0.78 | KMT2A (0.64) | CYP19A1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12045326 | 0.77 | TP53 (0.71) | CYP19A1KMT2ATP53KDM4ETSHR | |
| Hydrochloric Acid SCHEMBL9663915 | 0.77 | CYP19A1 (0.97) | CYP19A1KMT2AMAOAMAOBQPCT | |
| SCHEMBL6642525 | 0.77 | QPCT (0.64) | CYP19A1KMT2AKDM4EPOLBQPCT | |
| Hydrochloric Acid SCHEMBL9996062 | 0.76 | TP53 (0.69) | CYP19A1KMT2ATP53KDM4ETSHR | |
| SCHEMBL5655099 | 0.76 | CYP19A1 (0.84) | CYP19A1KMT2AMAOAMAOBQPCT | |
| SCHEMBL19925993 | 0.76 | NOS1 (0.65) | CYP19A1KMT2AKDM4EQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | CYP19A1 86/4885KMT2A 391/4885TP53 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.